The use of long-term sulfonyluria drugs in patients with type 2 diabetes leads to reduced glucagon levels in the blood, and this may contribute to lowering blood sugar by these drugs.
The mechanism of action of these drugs to reduce glucagon levels is not entirely clear, but this may be due to an indirect effect by increasing the release of insulin and somatostatin, which in turn inhibit the secretion of cells in the pancreas (A cells).
In the absence of beta cells, as in patients with type 1 diabetes, as well as in experimental animals who have diabetes using streptozacin, sulfonyluria drugs actually lead to a slight increase in glucagon secretion.
The mechanism of action of these drugs to reduce glucagon levels is not entirely clear, but this may be due to an indirect effect by increasing the release of insulin and somatostatin, which in turn inhibit the secretion of cells in the pancreas (A cells).
In the absence of beta cells, as in patients with type 1 diabetes, as well as in experimental animals who have diabetes using streptozacin, sulfonyluria drugs actually lead to a slight increase in glucagon secretion.
Labels
SULFONYL UREA DRUGS